
-
Editas Medicine NasdaqGS:EDIT Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Location: 11 Hurley Street, Cambridge, MA, 02141, United States | Website: https://www.editasmedicine.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-36.64M
Cash
221M
Avg Qtr Burn
-52.05M
Short % of Float
10.90%
Insider Ownership
0.35%
Institutional Own.
56.42%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Genetic disorder, Beta thalessemia | Failed Discontinued | |
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Sickle cell disease, Genetic disorder | Failed Discontinued | |
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C | Failed Discontinued |